All In Biotech

NDA 220415 · Abbvie

Juvmo

Tavapadon · Oral

Novel

CDER novel approval, Sep 25, 2026: To treat Parkinson's disease in adults

Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2026

Sep 25, 2026

Approved uses

1

Original approval plus efficacy supplements

Registered trials

10

4 Phase 3, 0 recruiting

FAERS reports

1

1 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 8, 2026.

JUVMO is indicated for the treatment of Parkinson’s disease (PD) in adults. JUVMO is a non-ergot dopamine agonist indicated for the treatment of Parkinson’s disease in adults. ( 1 )

Mechanism: Tavapadon is a selective partial agonist at the dopamine D1 and D5 receptor subtypes (D 1 /D 5 ).

Therapeutic areas: Neurology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 25, 2026 Original approval · Type 1 - New Molecular Entity NovelLetterLabelReview
5 products under this application
  • JUVMO · TAVAPADON 15MG · TABLET, ORAL · Prescription
  • JUVMO · TAVAPADON 5MG · TABLET, ORAL · Prescription
  • JUVMO · TAVAPADON 15MG · TABLET, ORAL · Prescription
  • JUVMO · TAVAPADON 10MG · TABLET, ORAL · Prescription
  • JUVMO (COPACKAGED) · TAVAPADON 0.25MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Tavapadon" as an intervention, any sponsor and status, largest first.

All 10 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • anxiety disorder1
  • cough1
  • hallucination1
  • panic attack1
  • parkinson^s disease1
  • therapeutic product effect incomplete1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20211

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 5 on PubMed

Sponsor: AbbVie · Also marketed as Juvmo (Copackaged)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.